GlobeNewswire Inc.··NaInventiva Banks on MASH Drug Data as Cash Runway Extends to 2027
Inventiva reports €196.5M liquidity with runway through mid-2027, awaiting Q4 2026 Phase 3 lanifibranor results for MASH treatment.
IVAcash positionclinical-stage biotech